PRAX-628
Focal Onset Seizures
Key Facts
About Praxis Precision Medicines
Praxis Precision Medicines is a clinical-stage biotech company with a mission to revolutionize neurology by developing precision therapies for CNS disorders, leveraging a proprietary platform built on human genetics, translational tools, patient-guided development, and rigorous clinical paths. The company has achieved significant valuation growth, driven by a promising pipeline targeting rare genetic epilepsies, essential tremor, and focal seizures, with multiple late-stage clinical programs underway. Its strategy focuses on de-risking development through genetic validation and efficient trial designs to address devastating, high-unmet-need conditions.
View full company profileTherapeutic Areas
Other Focal Onset Seizures Drugs
| Drug | Company | Phase |
|---|---|---|
| Azetukalner (XEN1101) | Xenon Pharmaceuticals | Phase 3 |